Immunotherapy using immune checkpoint inhibitors (ICI) has revolutionized the treatment landscape in oncology, but significant challenges remain. Without reliable tools to identify likely responders, patients who may have responded are not prescribed ICIs.
However, the development of more predictive biomarkers has shown promise in allowing oncologists to better select patients who may benefit from this method of immunotherapy.
Download this eBook to learn more about:
- How to harness spatial biology to bridge the immuno-oncology biomarker gap
- Spatial biomarkers and multiplex immunofluorescence in immuno-oncology
- Developing a reproducible multiplex imaging workflow
- Multiplex imaging analysis
